

Hamps Bio Ltd.

(Previously Known as Hamps Bio Pvt. Ltd.)

Date: May 28, 2025

To,
The Manager
BSE Limited
1st Floor, New Trading Ring,
Phiroze Jeejeebhoy Towers, Dalal
Street, Fort,
Mumbai 400001 (Maharashtra)

Scrip Code: 544312

Subject: Outcome of the Board Meeting of HAMPS BIO LIMITED held on Wednesday, May 28, 2025, pursuant to the Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sir/ Madam,

We hereby inform you that in continuation to our letter for intimation of Board Meeting and pursuant to the requirements of the Regulation 30 and 33 of the Listing Regulations, as amended, from time to time, the Board of Directors of the Company, at their meeting held on **Wednesday, May 28, 2025** at the Registered Office of the Company, have *inter-alia* considered the following:

1. Approved the Audited Standalone Financial Results of the Company for the half year and financial year ended on March 31, 2025, along with the Statement of Assets and Liabilities as at March 31, 2025 and Statement of Cash Flow for the financial year ended on March 31, 2025.
2. Took note of the Auditor's Report with unmodified opinion on the Audited Standalone Financial Results for the half year and financial year ended on March 31, 2025, issued by M/s MGVS & ASSOCIATES, Chartered Accountants, Statutory Auditor of the Company and the same is enclosed herewith.

Further, a copy of the declaration pursuant to Regulation 33(3)(d) of the Listing Regulations, with respect to the Auditor's Report issued by the Statutory Auditor with unmodified opinion on the above-mentioned Audited Standalone Financial Results issued in enclosed herewith as **Annexure A**.

3. Recommended the appointment of M/s Richa Goyal & Associates, Practising Company Secretary, Surat as Secretarial Auditor of the company, for first term of 5 (Five) consecutive years, with effect from April 01, 2025 to March 31, 2030, subject to the approval of the Members at the ensuing Annual General Meeting ("AGM") of the Company.

CIN No. : L24233GJ2007PLC049692

Factory : Unit - 1 : 2900/112, G.I.D.C. Industrial Estate, Nr. Atul Ltd., Ankleshwar - 393002

Unit - 2 : Plot No. C1-B-106, Nr- Mama Bhanja Factory, Bhatpore G.I.D.C., Surat, Gujarat, India 394510

E-mail : hamps.bio@gmail.com, Web : www.hampsbio.com, Mo.No. : 8000001113, 8000006663

Hamps Bio Ltd.

(Previously Known as Hamps Bio Pvt. Ltd.)

4. Approved the appointment of M/s Naviwala & Associates, Surat as Internal Auditor of the Company for the Financial Year 2025-2026, effective from 28th May, 2025.

Additional information as required under Regulation 30 of Listing Regulations, read with the SEBI Circular bearing reference number SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 will be disclosed in due course

The Board Meeting commenced at 6:00 P.M (IST) and concluded at 8:00 P.M. (IST).

You are kindly requested to take the above on your record and update the same.

**Yours faithfully,
For HAMPS BIO LIMITED**

KOMAL
JAIN

Digitally signed by KOMAL JAIN
DN: cn=, o=Personal,
postalCode=392002, st=Rajasthan,
serialNumber=2027102111140001121
471399810FAD2CC8B37A1E8A1A
D3A9902742E201, ou=KOMAL JAIN
Date: 2025.05.28 21:51:22 +05'30'

MS. KOMAL JAIN
Company Secretary & Compliance Officer
Membership No.: ACS No. A40470

Enclosure: As above

CIN No. : L24233GJ2007PLC049692

Factory : Unit - 1 : 2900/112, G.I.D.C. Industrial Estate, Nr. Atul Ltd., Ankleshwar - 393002

Unit - 2 : Plot No. C1-B-106, Nr- Mama Bhanja Factory, Bhatpore G.I.D.C., Surat, Gujarat, India 394510

E-mail : hamps.bio@gmail.com, Web : www.hampsbio.com, Mo.No. : 8000001113, 8000006663



MGVS & ASSOCIATES
Chartered Accountants

8154912316, 9265096979
7048388605, 9737211161

802-A, TRIVIDH CHAMBERS, OPP. MAAN DARWAJA FIRE STATION, RING ROAD, SURAT, GUJARAT-395002

Independent Auditors' Report on Half Yearly and Year to Date Financial Results of Hamps Bio Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
M/s. HAMPS BIO LIMITED

Opinion

We have audited the accompanying statement of financial results of **Hamps Bio Limited** (the company) for half year ended 31st March, 2025 and year to date results for the period from 1st April 2024 to 31st March 2025 (the "Statement"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other financial information for the half year ended 31" March 2025 and year to date results for the period from 1" April 2024 to 31" March 2025.





MGVS & ASSOCIATES
Chartered Accountants

8154912316, 9265096979
7048388605, 9737211161

802-A, TRIVIDH CHAMBERS, OPP. MAAN DARWAJA FIRE STATION, RING ROAD, SURAT, GUJARAT-395002

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit for the Annual Financial Results section of our report.

We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion the financial results.

Management's Responsibilities for the Financial Results

These financial results have been prepared based on the annual financial statements. The Company's Management and the Board of Directors are responsible for the preparation and presentation of these annual financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation





MGVS & ASSOCIATES
Chartered Accountants

8154912316, 9265096979
7048388605, 9737211161

802-A, TRIVIDH CHAMBERS, OPP. MAAN DARWAJA FIRE STATION, RING ROAD, SURAT, GUJARAT-395002

and presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i)





MGVS & ASSOCIATES
Chartered Accountants

8154912316, 9265096979
7048388605, 9737211161

802-A, TRIVIDH CHAMBERS, OPP. MAAN DARWAJA FIRE STATION, RING ROAD, SURAT, GUJARAT-395002

of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the financial results made by the Board of Directors.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.





MGVS & ASSOCIATES
Chartered Accountants

8154912316, 9265096979
7048388605, 9737211161

802-A, TRIVIDH CHAMBERS, OPP. MAAN DARWAJA FIRE STATION, RING ROAD, SURAT, GUJARAT-395002

Other Matter

The Statement includes the results for the half year ended 31" March 2025 being the balancing figures between the audited figures in respect of the full financial year ended 31" March 2025 and the published unaudited year to date figures up to the period ended 30th September 2024 which were subjected to a limited review by us, as required under the Listing Regulations. Moreover, the comparative financial information for the half year ended 31" March 2024 were not subject to limited review/audit by us and the same has been presented solely based on the information compiled by the management. Our report is not modified in respect of this matter

For M G V S & ASSOCIATES
Chartered Accountants



CA MUBASSIR M GODIL
(Partner)

M. No: 164503

FRN: 140555W

Place: Surat

Date: 28/05/2025

UDIN: 25164503BMHUBN8041

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)		
(CIN: L24233G12007PLC049692)		
(Address: 2900/112, Near Atul Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393002)		
Balance Sheet as at 31st March 2025		
	(Rs. in Lakhs)	
Particulars	31 March 2025	31 March 2024
I. EQUITY AND LIABILITIES		
(1) Shareholders' funds		
(a) Share Capital	435.60	196.00
(b) Reserves and Surplus	444.45	138.44
Total	880.05	334.44
(2) Non-current liabilities		
(a) Long-term Borrowings	202.67	29.55
(b) Other Long-term Liabilities	9.41	7.33
Total	212.08	36.88
(3) Current liabilities		
(a) Short-term Borrowings	94.06	74.97
(b) Trade Payables		
- Due to Micro and Small Enterprises	0.07	19.51
- Due to Others	60.17	8.17
(c) Other Current Liabilities	20.89	20.99
(d) Short-term Provisions	12.16	16.83
Total	187.35	140.47
Total Equity and Liabilities	1,279.48	511.79
II. ASSETS		
(1) Non-current assets		
(a) Property, Plant and Equipment and Intangible Assets		
(i) Property, Plant and Equipment	248.18	252.37
(ii) Capital Work-in-progress	327.60	-
(iii) Intangible assets under development	10.80	-
(b) Non-current Investments	0.12	0.12
(c) Deferred Tax Assets (net)	7.04	6.30
(d) Other Non-current Assets	261.70	9.31
Total	855.44	268.09
(2) Current assets		
(a) Inventories	238.00	122.82
(b) Trade Receivables	119.22	98.94
(c) Cash and cash equivalents	9.57	5.84
(d) Short-term Loans and Advances	1.20	12.43
(e) Other Current Assets	56.06	3.68
Total	424.04	243.70
Total Assets	1,279.48	511.79

See accompanying notes to the financial statements

For and on behalf of the Board of Directors

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

FOR, HAMPS BIO LIMITED

MANAGING DIRECTOR
DIN : 01052316

MANAGING DIRECTOR

01052316

Place: ANKLESHWAR

Date:

FOR, HAMPS BIO LIMITED

WHOLE TIME DIRECTOR

DIN : 00973690

WHOLE TIME DIRECTOR

00973690



HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)
 [CIN: 124233G/2007PLC049692]
 [Address: 2900/112, Near Atul Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393002]
Statement of Financial Results for the Half Year ended and Year ended March 31,2025
 (Rs. in Lakhs)


Particulars	6 Months ended			Year Ended	
	31/03/2025	30/09/2024	31/03/2024	31/03/2025	31/03/2024
	Audited	Unaudited	Unaudited	Audited	Audited
Revenue from Operations	312.86	354.01	332.92	666.87	647.53
Other Income	6.70	8.41	2.02	15.11	2.60
Total Income	319.56	362.42	334.94	681.98	650.13
Expenses					
Cost of Material Consumed	49.39	35.84	36.18	85.24	31.06
Purchases of Stock in Trade	97.00	104.11	96.45	201.11	217.10
Change in Inventories of work in progress and finished goods	(60.78)	(25.65)	(45.63)	(86.43)	(77.81)
Employee Benefit Expenses	96.72	92.79	92.08	189.52	170.83
Finance Costs	5.94	8.01	5.95	13.95	14.97
Depreciation and Amortization Expenses	18.78	18.93	19.78	37.71	40.36
Other Expenses	108.27	92.24	99.21	200.51	188.63
Total expenses	315.33	326.27	304.02	641.60	585.13
Profit/(Loss) before Exceptional and Extraordinary Item and Tax	4.23	36.15	30.93	40.39	64.99
Exceptional Item				-	-
Profit/(Loss) before Extraordinary Item and Tax	4.23	36.15	30.93	40.39	64.99
Extraordinary Item				-	-
Profit/(Loss) before Tax	4.23	36.15	30.93	40.39	64.99
Tax Expenses					
- Current Tax	1.08	10.28	8.27	11.35	16.58
- Deferred Tax	(0.11)	(0.63)	(0.49)	(0.74)	(1.66)
Profit/(Loss) after Tax	3.27	26.50	23.14	29.77	50.06
Earnings Per Share (Face Value per Share Rs.10 each)					
-Basic (In Rs)	0.08	0.85	1.18	0.68	2.55
-Diluted (In Rs)	0.08	0.85	1.18	0.68	2.55

See accompanying notes to the financial statements

For and on behalf of the Board of Directors

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

FOR, HAMPS BIO LIMITED


MANAGING DIRECTOR
 DIN: 01052316

MANAGING DIRECTOR
 01052316
 Place: ANKLESHWAR
 Date:

FOR, HAMPS BIO LIMITED


WHOLE TIME DIRECTOR
 DIN: 00973690
 WHOLE TIME
 00973690



HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

(CIN: L24231GJ2007PLC090992)

(Address: 2000/112, Near Atal Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393007)

Cash Flow Statement for the year ended 31 March 2025

	(Rs. in Lakhs)	
Particulars	31 March 2025	31 March 2024
CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit after tax	29.77	50.06
Profit/(Loss) from Discontinuing Operation (after tax)	-	-
Depreciation and Amortisation Expense	37.71	40.36
Provision for Tax	10.61	14.93
Other Adjustments	-	(4.59)
Interest Income	(4.42)	(0.47)
Finance Costs	13.95	14.97
Operating Profit before working capital changes	87.62	115.25
Adjustment for:		
Inventories	(115.18)	(86.10)
Trade Receivables	(20.28)	(22.97)
Loans and Advances	11.23	(12.43)
Other Current Assets	(52.38)	1.98
Movement in deferred tax asset	(0.74)	(1.66)
Trade Payables	32.57	(23.08)
Other Current Liabilities	(0.10)	(9.39)
Short-term Provisions	(4.67)	16.83
Long-term Provisions	2.08	7.33
Cash (Used in)/Generated from Operations	(50.85)	(14.22)
Tax paid/(Net)	10.61	14.93
Net Cash (Used in)/Generated from Operating Activities	(70.47)	(29.15)
CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant and Equipment	(371.92)	(36.20)
Proceeds from Sale / Redemption of Mutual Funds	-	0.15
Movement in other non current assets	(252.40)	(1.10)
Interest received	4.42	0.47
Dividend received	-	-
Net Cash (Used in)/Generated from Investing Activities	(619.89)	(36.67)
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of Share Capital	622.20	151.00
Issue Expense	(106.36)	-
Proceeds from Long Term Borrowings	184.94	-
Repayment of Long Term Borrowings	(11.83)	(12.06)
Proceeds from Short Term Borrowings	30.28	-
Repayment of Short Term Borrowings	(11.19)	(57.18)
Interest Paid	(13.95)	(14.97)
Net Cash (Used in)/Generated from Financing Activities	694.09	66.78
Net Increase/(Decrease) in Cash and Cash Equivalents	3.73	0.96
Opening Balance of Cash and Cash Equivalents	5.84	4.88
Exchange difference of Foreign Currency Cash and Cash equivalents	-	-
Closing Balance of Cash and Cash Equivalents	9.57	5.84

Note:

The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard 3 (AS-3), "Cash Flow

See accompanying notes to the financial statements

For and on behalf of the Board of Directors

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

FOR, HAMPS BIO LIMITED

MANAGING DIRECTOR
DIN: 00052316

FOR, HAMPS BIO LIMITED

WHOLE TIME DIRECTOR
DIN: 00973690

WHOLE TIME DIRECTOR
00973690



HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)
NOTES TO FINANCIAL RESULTS
CIN: L24233GJ2007PLC049692


1. The above financial results were reviewed by the audit committee and then approved by the board of directors in their meeting held on 28th May 2025
2. The results for the half year ended September 2024 are reviewed by the statutory auditor of the company in the compliance with the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
3. These financial results prepared in accordance with the recognition and measurement principals of accounting standard (AS) prescribed under section 133 of the companies act 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India.
4. The Earning Per Share (EPS) have been computed in accordance with Accounting Standard on Earning Per Share (EPS) AS-20
5. The comparative results for the half year ended 31st March 2024 have not been audited/reviewed by the statutory auditors of the company. The management has exercised due diligence to ensure that the said comparative results provide true & fair view
6. The figures for the half year ended March 2025 & March 2024 are the balancing figures between the audited figures in respect of full financial year and the figures up to half year ended September 2024 and September 2023 respectively
7. Based on guiding principles given in the Accounting standard on 'Segment Reporting' (AS-17), the business segment of the Company is trading of medicines (Pharma) and of manufacturing of Freeze dried products. The details of the same is as follows:

Year ended 31st March, 2025	Pharma Products (Rs. in Lakhs)	Freeze dried Products (Rs. in Lakhs)	Total (Rs. in Lakhs)
Segment Revenue	347.59	319.29	666.87
Segment Assets	160.23	728.20	888.43
Segment Liabilities	42.88	17.64	60.52

Note: Segment results are not reported, as it is not possible to compute segment net profit or loss, or any other measure of segment profitability, without arbitrary allocations. The company is engaged in the manufacturing of freeze dried products and trading of pharmaceutical products. As a result, fixed assets are allocated to the freeze dried products segment and only details of debtors and stock are included in Pharma segment.


8. The company has made Initial Public offering of 12,20,000 equity shares comprising a Fresh Issue of 12,20,000 Equity shares of Face Value of Rs.10 Each at a premium of Rs.41 each and got listed on Bombay Stock Exchange - SME on 20th December 2024.

FOR, HAMPS BIO LIMITED


MANAGING DIRECTOR
DIN : 01052316

FOR, HAMPS BIO LIMITED


WHOLE TIME DIRECTOR
DIN : 00973690



9. The previous year figures have been regrouped/reclassified wherever necessary to correspond with the current year classification for the comparison

10. The Company's inventory comprises Raw Materials, Finished Goods, and Stock-in-Trade. Inventories are valued at the lower of cost or net realizable value, in accordance with applicable accounting standards and the Company's accounting policy. The Management has derived the valuation of inventory based on FIFO method and includes all costs incurred in bringing the inventories to their present location and condition.

11. The Company has utilised proceeds from IPO as per the Object clause of the Prospectus as details below

Particulars	Proceeds (Rs in Lakhs)	Utilisation up to March 31st, 2025	Unutilised up to March 31st, 2025 **
Purchase of Plant and Machinery & construction activity for FMCG division	359.00	208.00	151.00
Enhancing the visibility and awareness of the brand	50.00	17.14	32.86
General corporate purposes*	94.20	94.20	-
Issue Expenses Paid	119.00	119.00	-
Total	622.20	438.34	183.86

(*The amount utilized for general corporate purpose is not exceeding 25% of the gross proceeds of the issue)

(**The above unutilized amount as at 31st March 2025, has been kept in the form of Fixed Deposits and Overdraft (OD) accounts with scheduled bank)

During the year, the Company undertook expansion by way of purchase of Plant and Machinery and carried out construction activity pertaining to the FMCG division. The expenditure incurred includes components related to the acquisition of fixed assets, which have been capitalized in accordance with applicable accounting standards.

The associated operating and running costs have been charged to the Statement of Profit and Loss as and when incurred.

During the year, the Company has acquired solar energy systems which are intended to be put to use in the subsequent financial year. As these assets require a substantial period of time to get ready for their intended use, they qualify as Qualifying Assets. Accordingly, the cost of such solar energy systems has been capitalized under fixed assets. Further, in compliance with the accounting standards, interest on term loans specifically borrowed for the acquisition of these assets, along with other directly attributable expenditures such as security deposits, have also been capitalized as part of the cost of the qualifying assets.


Further, expenses incurred towards product development have been capitalized, being in the nature of capital expenditure, and are expected to generate future economic benefits.

FOR, HAMPS BIO LIMITED


MANAGING DIRECTOR
DIN : 01052316

FOR, HAMPS BIO LIMITED


WHOLE TIME DIRECTOR
DIN : 00973690



For and on behalf of

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

CIN: L24233GJ2007PLC049692

FOR, HAMPS BIO LIMITED


MANAGING DIRECTOR

DIN : 01052316

Herrik Shah

Managing Director

DIN : 01052316

FOR, HAMPS BIO LIMITED


WHOLE TIME DIRECTOR

DIN : 00973690

Shrenik Shah

Whole Time Director

DIN : 00973690

Hamps Bio Ltd.

(Previously Known as Hamps Bio Pvt. Ltd.)

Date: May 28, 2025

To,
The Manager
BSE Limited
1st Floor, New Trading Ring,
Phiroze Jeejeebhoy Towers, Dalal Street, Fort,
Mumbai 400001 (Maharashtra)

Scrip Code: 544312

Subject: Declaration pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sir/ Madam,

The Board of Directors of the company, at their meeting held on **Wednesday, May 28, 2025** has considered and approved the Audited Standalone Financial Results of the Company for the Half year and Financial year ended on March 31, 2025 and further, pursuant to the Regulation 33(3)(d) of the Listing Regulations, we hereby declare and confirm that M/S MGVS & ASSOCIATES, Chartered Accountants, Statutory Auditor of the Company, have issued an Audit Report with unmodified opinion on the Audited Standalone Financial Results of the Company for the Half year and Financial year ended on March 31, 2025.

You are kindly requested to take the above on your record and update the same.

Yours faithfully,

For Hamps Bio Limited

HERRIK
MOUNTBAT
ON SHAH

Digitaly signed by HERRIK
MOUNTBATON SHAH
DIN: 01052316
pincode: 395002, in Gujarat,
serialNumber=00011533CC733A5E1A
508FE2F8AC334A34B038116A99
SHA1MIMEDEL: 00=HERRIK
MOUNTBATON SHAH
Date: 2025.05.28 21:52:00 +05'30'

HERRIK MOUNTBATON SHAH
Managing Director & Chairman
DIN: 01052316

CIN No. : L24233GJ2007PLC049692

Factory : Unit - 1 : 2900/112, G.I.D.C. Industrial Estate, Nr. Atul Ltd., Ankleshwar - 393002

Unit - 2 : Plot No. C1-B-106, Nr- Mama Bhanja Factory, Bhatpore G.I.D.C., Surat, Gujarat, India 394510

E-mail : hamps.bio@gmail.com, Web : www.hampsbio.com, Mo.No. : 8000001113, 8000006663